Cytek Q3 revenue $40.5M (+18% YoY); net income $1.6M; guides FY near high end of $160-168M

Cytek Biosciences, Inc.

2022-Q3 EPS reported -$0.01 revenue$115,700,000

Revenue $40.5M (+18% YoY); gross margin improved to 66.4% from 61.9%.
Net income $1.6M (vs $1.4M); adjusted EBITDA $7.3M (vs $5.5M).
FY2022 revenue guidance reaffirmed closer to high end of $160M-$168M range.
Appointed Chris Williams as Chief Operating Officer during the quarter.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cytek Biosciences, Inc. reported the third quarter ended September 30, 2022 results: revenue $40.5 million, net income $1.6 million. Guidance reaffirmed.

Period: the third quarter ended September 30, 2022
Revenue: $40.5 million
Net income: $1.6 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenue was $40.5 million for the third quarter, representing an 18% increase over the corresponding quarter of 2021

View on SEC.gov

Browse all earnings releases →

Cytek Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-281247

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.